
Gyre Therapeutics, Inc.: updates and filings
Price
$4.21
November 20, 2026Market cap $486M
What Ploutos Investor adds for Gyre Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 5, 2026next Feb 5, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
October 2026
August 2026
July 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 6, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 5, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 22, 2026Officer or director changeForm8-K
- Sep 1, 2026Regulation FD disclosureForm8-K
- Aug 27, 2026Shares registered for employeesFormS-8
- Aug 26, 2026Regulation FD disclosureForm8-K
- Aug 7, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 7, 2026Results of operationsForm8-K
- Aug 3, 2026FilingFormEFFECT
- Jul 16, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jul 15, 2026Results of operations (amendment)Form8-K/A
- Jul 13, 2026Shelf registration for future offerings (amendment)FormS-3/A
- Jun 23, 2026Shelf registration for future offeringsFormS-3
- Jun 16, 2026Shareholder voteForm8-K
- Jun 10, 2026Shares registered for employeesFormS-8
- Jun 2, 2026Regulation FD disclosureForm8-K
- May 14, 2026Regulation FD disclosureForm8-K
- May 12, 2026Regulation FD disclosureForm8-K
- May 8, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 7, 2026Results of operationsForm8-K
- May 6, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 6, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 4, 2026Additional annual meeting materialFormDEFA14A
- May 4, 2026Acquisition or disposal of assets, unregistered sale of shares, change to shareholders' rights, officer or director change, amended articles or bylaws, Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 6, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 5, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 22, 2026 | 8-K | Officer or director change | Document |
| Sep 1, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 27, 2026 | S-8 | Shares registered for employees | Document |
| Aug 26, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 7, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 7, 2026 | 8-K | Results of operations | Document |
| Aug 3, 2026 | EFFECT | Filing | Document |
| Jul 16, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jul 15, 2026 | 8-K/A | Results of operations (amendment) | Document |
| Jul 13, 2026 | S-3/A | Shelf registration for future offerings (amendment) | Document |
| Jun 23, 2026 | S-3 | Shelf registration for future offerings | Document |
| Jun 16, 2026 | 8-K | Shareholder vote | Document |
| Jun 10, 2026 | S-8 | Shares registered for employees | Document |
| Jun 2, 2026 | 8-K | Regulation FD disclosure | Document |
| May 14, 2026 | 8-K | Regulation FD disclosure | Document |
| May 12, 2026 | 8-K | Regulation FD disclosure | Document |
| May 8, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 6, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 4, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 4, 2026 | 8-K | Acquisition or disposal of assets, unregistered sale of shares, change to shareholders' rights, officer or director change, amended articles or bylaws, Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Dec 16, 2002: every report, 8-K, meeting and letter. Of its other filings (843 in all), the newest.
The full analysis
What do Gyre Therapeutics's filings show?
The filings are where every one of Gyre Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.